Corrigendum

Abstract

Steven G. Potkin, Tatsuya Kimura and John Guarino. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Therapeutic Advances in Psychopharmacology 2045125315606027, first published on October 9, 2015. [Doi:10.1177/2045125315606027]

It has come to our attention that there were errors in Table 5, which appear to have been introduced during the conversion to SI units. Several of the values in Table 5 were not converted from mg/dL to mmol/L.

The corrected table 5 has now been included below:

Table 5.

Changes in weight and laboratory parameters at week 6 (last observation carried forward, safety population).

Measure	Lurasidone 20 mg/day(n = 71)	Lurasidone 40 mg/day(n = 67)	Lurasidone 80 mg/day(n = 71)	Haloperidol 10 mg/day(n = 72)	Placebo(n = 72)
Weight (kg), mean (SD)
Baseline  Change	83.8 (20.3) -0.2 (2.6)	87.2 (21.2) 0.0 (3.6)	91.0 (21.5) 0.9 (4.2)	88.4 (20.2) 0.1 (3.1)	84.8 (22.9) 0.1 (3.0)
> 7% weight gain, n (%)	1 (1.5)	2 (3.0)	4 (5.7)	3 (4.3)	2 (2.9)
Total cholesterol, mmol/l
Baseline mean (SD)  Median change	5.2 (1.3) -0.3	5.3 (1.0) -0.5	5.4 (1.2) -0.3	5.2 (1.5) -0.2	5.1 (1.0) -0.3
Triglycerides, mmol/l
Baseline mean (SD)  Median change	2.1 (1.5) -0.1	2.0 (1.1) -0.1	2.3 (1.7) -0.2	2.1 (1.8) -0.1	2.0 (1.4) -0.1
Glucose, mmol/l
Baseline mean (SD)  Median change	5.7 (1.3) -0.1	5.3 (0.9) 0.1	5.7 (1.9) 0.1	5.4 (1.1) 0.1	5.5 (1.4) -0.2
Prolactin, ng/ml, men
Baseline mean (SD)  Median change	11.8 (8.2) -1.1	14.7 (12.0) 0.1	11.5 (8.9) 1.1	11.3 (6.3) 8.4	11.8 (8.3) -2.1
Prolactin, ng/ml, women
Baseline mean (SD)  Median change	13.3 (10.2) -0.7	23.9 (21.4) -1.3	15.9 (11.4) -1.0	22.5 (29.5) 27.6	21.2 (11.9) -7.9

SD, standard deviation.